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Abstract-The two enantiomers of 2’,3’-dideoxy-3’-thiacytidine (BCH-189) and their S-fluoro analogs 
(FTC) were found to be good substrates for human 2’-deoxycytidine kinase with K,,, values in the 5.7 
to 42.1 PM range. The affinity of the (-)-enantiomers was greater than that of the (+)-compounds. 
These results may explain the greater in vitro antiviral potency against human immunodeficiency virus 
and hepatitis B virus of the (-)-enantiomers when compared to their (+)-counterparts. The (+)- and 
(-)-enantiomers of FTC and BCH-189 are the first nucleoside analogs for which we have observed 
lower apparent kinetic constants for this enzyme in the presence of ATP compared to UTP. 
Oxathiolane cytosine nucleosides represent a promising 
new class of compounds with potent and selective antiviral 
activity against human immunodeficiency virus (HIV)* and 
hepatitis B virus (HBV) [l-12]. Racemic 2’,3’-dideoxy-3’- 
thiacytidine (BCH-189) and 2’,3’-dideoxy-5-fluoro-3’- 
thiacytidine (FTC) were found to be active at submicromolar 
concentrations against these viruses in culture. This led to 
the separation or synthesis of the two possible enantiomers 
of these compounds by HPLC, by developing a synthesis 
using chiral sugars, and by using the enantioselectivity of 
certain enzymes such as cytosine deaminases and lipases 
to hydrolyze only one of the enantiomers [2-4,9, lo]. 
Unexpectedly, the unnatural (-)-enantiomers were found 
to be the more potent enantiomers in various cell culture 
systems [l, 4,9,10]. The (-)-enantiomers were also less 
toxic to the lymphoblastoid CEM cells and primary human 
bone marrow cells than the (+)-isomers [l, 2,121. Metabolic 
studies in human cells have demonstrated the efficient and 
rapid conversion of the enantiomers of BCH-189 and FTC 
to their corresponding 5’-triphosphates [4,5]. The 5’- 
triphosphate of the (-)-enantiomers are potent competitive 
inhibitors with respect to 2’-deoxycytidine-5’-triphosphate 
against HIV reverse transcriptase (RT) and are weak 
inhibitors of human DNA polymerases [2,13]. These 
nucleotides have been shown to act as chain terminators 
of the viral DNA catalyzed by the viral RT in cell-free 
systems. The low toxicity and favorable potency of (-)- 
BCH-189 (3TC) and (-)-FTC compared to the (+)- 
compounds led to the selection of the (-)-enantiomers as 
candidates for the treatment of viral infections in humans. 
We determined recently that racemic FTC was 
phosohorvlated in wild-tvpe CEM cells. but not in 2’- 
beoxycytidine kinase (dCydK)-deficient cells (data not 
shown), suggesting a unique role for dCydK in the 
activation of both the (+)- and (-)-enantiomers. We also 
ruled out 5’-nucleotidase as the phosphorylating enzyme 
since mycophenolic acid, which increases 5’nucleotidase 
activity by elevating IMP levels (141, did not enhance 
phosphorylation of FTC. The anti-HIV activity of FTC 
and BCH-189 and their enantiomers was abolished in the 
presence of 2’-deoxycytidine, but not other natural 2’- 
deoxynucleosides [2]. Metabolic studies with radiolabeled 
compounds in uninfected human peripheral blood mono- 
* Abbreviations: HIV, human immunodeficiency virus; 
HBV, hepatitis B virus; BCH-189, 2’,3’-dideoxy-3’- 
thiacytidine; FTC, 2’,3’-dideoxy-5-fluoro-3’-thiacytidine; 
RT, reverse transcriptase; PBM, peripheral blood mono- 
nuclear; CDA, cytidine deaminase; araC, l-/I-D-ara- 
binofuranosylcytosine; FaraA, 9$-D-arabinofuranosyl-2- 
fluoroadenine; DDC, 2’,3’-dideoxycytidine; dFdC, 2’,2’- 
difluoro-2’-deoxycytidine;dCydK,2’-deoxycytidine kinase. 
nuclear (PBM) cells demonstrated that the total levels of 
nucleotides in these cells over a period of 2-48 hr were 2- 
to 3.2-fold greater with (-)-BCH-189 and (-)-FTC than 
with (+)-BCH-189 and (+)-FTC (data not shown). 
Whereas the (-)-enantiomers are essentially resistant to 
cytidine deaminase (CDA), (+)-BCH-189 and (+)-FTC 
are susceptible to deamination and could account for the 
lower levels of their phosphorylated derivatives noted in 
cell culture [>5]. However, tetrahydrouridine or 2’- 
deoxytetrahydrouridine, potent inhibitors of CDA and 
cytidylate deaminase, do not enhance the anti-HIV activity 
of (+)-FTC in PBM cells [2]. A more likely explanation 
for the difference in potency of the (+)- and (-)- 
enantiomers may be the lower affinity of (+)-FTC and 
(+)-BCH-189for humandCydK. Therefore, we determined 
the affinity of human dCydK for these compounds using 
different natural nucleosides as phosphate donors. 
Materials and Methods 
Materials. The pyrimidine nucleosides were synthesized 
in our laboratories as previously described [9, 151. 
Radioactive racemic ( +)-[5-3H]BCH-189 (sp. act. 29 Ci/ 
mmol), (-)-[5-3H]BCH-189 (14 Ci/mmol), (-)-[6--‘HI- 
FTC (9 Ci/mmol) and ( +)-(6-3H]FTC (9 Ci/mmol) were 
synthesized by our group in collaboration with Moravek 
Biochemicals, Brea, CA. The detailed synthesis and 
characterization of these compounds will be described 
elsewhere. (+)-[5-3H]BCH-189 (14.5 Ci/mmol) was pre- 
pared by separating it from radiolabeled racemic BCH-189 
using a previously described high pressure liquid 
chromatographic procedure [l]. The purity of all the 
unlabeled and radiolabeled compounds was greater than 
97.5% as determined by chiral column chromatography 
[l, 21. Natural nucleosides and nucleotides were of the 
highest purity available (Sigma Chemical Co., St. Louis, 
MO). Synthetic nucleotide analogs were prepared as 
described previously [2,5]. 
Enzyme purification. Human dCydK was isolated from 
actively growing MOLT-4 cells and purified by sequential 
steps of ammonium sulfate precipitation. HPLC-eel 
filtration, and DE-52 ion exchange chromatography, aid 
further ourified bv dffP-Seoharose affinitv chroma- 
tography’as described previously (161. ’ 
Enzyme assays. These studies utilized a preparation from 
MOLT-4 T lymphoblasts purified to > 80% homogeneity 
as described previously [16, 171. Stock solutions of the 
compounds were prepared in 50mM imidazole, pH7.0. 
The enzyme assay was performed in duplicate essentially 
as described previously (161. After desalting, the enzyme 
was incubated in a mixture containing 50 mM imidazole. 
pH 7.4, 25 mM dithiothreitol, 2 mM ATP or UTP, 2 mM 
MgQ, 5% glycerol, 100 mM KCI, 1 mg/mL bovine serum 
albumin, and tritiated nucleosides ranging in concentration 
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Table 1. Effect of phosphate donors on the kinetic constants for the phosphorylation of the 
enantiomers of FTC and BCH-189 by human dCydK 
JGl* V max* 
Compound Phosphate donor ( PM) (nmol . mL_‘. hr-‘) V,,JKm 
(+)-FTC UTP 42.1 6.2 0.15 
ATP 23.9 2.6 0.11 
(-)-FTC UTP 11.8 9.3 0.79 
ATP 7.4 3.8 0.51 
(+)-BCH-189 UTP 33.6 5.7 0.17 
ATP 17.6 1.7 0.09 
(-)-BCH-189 (3TC) UTP 9.9 6.5 0.66 
ATP 5.7 2.3 0.41 
dCyd UTP 0.25 24 96.0 
ATP 0.93 41 44.0 
DDC UTP 127.6 27.5 0.22 
ATP 78.5 11.6 0.15 
araC UTP 2.4 20.9 8.9 
ATP 14.8 62.4 4.2 
* Double-reciprocal plots of the data were linear. The results represent the averages of at least 
two experiments performed in duplicate. In general, the error was less than 10%. 
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from 3 to 100 PM in a final volume of 30 pL. The reaction 
mixture was incubated at 37” for 30 min and then inactivated 
at 85” for 1 min. The reaction rate was linear for at least 
40min. Reaction products were applied to DE81 filter 
discs, which were then washed with 5 mM ammonium 
formate to remove unreacted substrate. After drying, 
reaction products were eluted from the filter discs with 
0.5 mL of a solution containing 0.4 M KCI and 0.1 M HCI, 
5 mL of Biosafe scintillation fluid (Research Products 
International Corp., Mount Prospect, IL) was added, and 
radioactivity was quantitated in a Beckman LS6OOQ SC 
scintillation spectrometer. 
Kinetic analysis. The kinetic data were fitted to a 
hyperbola from which the apparent Km and V,,,,, values 
were calculated as described previously [ 161. 
Results and Discussion 
dCydK (EC 2.7.1.74) is an enzyme that catalyzes the 
phosphorylation of several natural and synthetic pyrimidine 
nucleosides to their corresponding 5’-monophosphates in 
the presence of a nucleoside-5’-triphosphate as the 
phosphate donor. The importance of this enzyme has been 
emphasized by the fact that it phosphorylates not only 2’- 
deoxycytidine (dCyd), but also certain clinically useful 
purine and pyrimidine nucleoside analogs. These include 
the antiviral and anticancer drugs 1-gD-arabinofurano- 
sylcytosine (araC), 9-/3-D-arabinofuranosyl-2-fluoro- 
adenine (FaraA), 2’,3’-dideoxycytidine (DDC), and 
2’,2’-difluoro-2’-deoxycytidine (dFdC) [l6,18]. We 
recentlvuurified dCvdK to near homoaeneitv from MOLT-4 
T lymphoblasts anddemonstrated tha’f UTP-is the preferred 
physiologic phosphate donor for this enzyme with either 
deoxyribosyl or arabinosyl nucleoside substrates (161. The 
availability of this highly purified enzyme, and the finding 
that certain oxathiolane nucleosides are phosphorylated 
only in cells expressing dCydK, prompted us to determine 
the kinetic constants and phosphate donor specificity of 
these novel enantiomeric antiviral agents. We hypothesized 
that these experiments could provide an insight into the 
enantiospecificity of dCydK and also provide a better 
understanding of the greater antiviral potency of the (-)- 
enantiomers of FTC and BCH-189. 
The enantiomers of FTC and BCH-189 exhibited good 
affinity for human dCydK based on micromolar Km values, 
although the apparent velocity was low compared to dCyd 
and araC (Table 1). The K,,, values were consistently lower 
for the (-)-enantiomers than for the (+)-counterparts 
irrespective of the phosphate donor. In addition, the (-)- 
enantiomers were more efficient substrates for dCydK than 
DDC. In striking contrast to our previous studies on the 
interactions of dCydK with dCyd, araC, dFdC and FaraA 
[16], the enantiomers of FlC and BCH-189 had lower 
apparent K,,, and V,,,,, values when ATP was used instead 
of UTP. However, the efficiency ratio of V,,,/K,, 
demonstrated a kinetic advantage for UTP as the phosphate 
donor, similar to our previous studies with other nucleoside 
analogs. Kinetic constants for the (+)-enantiomers were 
similar, while the corresponding values for the (-)- 
enantiomers were lower but comparable, indicating that 
the fluorine function at position 5 on FTC seemed to be 
well tolerated by dCydK. In each case, the (-)-enantiomer 
provided a 4- to 5-fold kinetic advantage over the (+)- 
stereoisomer (Table 1). These findings could account in 
part for the more potent antiviral activity in vitro of the 
(-)-enantiomers in human lymphocytes infected with HIV 
and in human liver cells transfected with HBV. 
We also evaluated the ability of the 5’-triphosphates of 
(-+)-FTC and (t)-BCH-189 to inhibit phosphorylation of 
the corresponding nucleosides. These studies demonstrated 
that 25 PM (+)-FIGTP or 100,uM (+)-BCH-l89-TP 
inhibited phosphorylation of the corresponding nucleoside 
by less than 10% when UTP was employed as the phosphate 
donor. In contrast, in the presence of ATP as the phosphate 
donor, 100 PM (+)-BCH-l89-TP inhibited phosphorylation 
of 10pM (-)-BCH-189 by greater than 80% (data not 
shown). These results are consistent with our previous 
report for dCTP inhibition of dCyd phosphorylation by 
dCydK, in which inhibition was apparent only when ATP 
was present as the phosphate donor [16]. Thus, under 
physiologic conditions, we predict that the 5’-triphosphate 
derivatives would not inhibit phosphorylation of (-)-FTC 
or (-)-BCH-189. 
The results presented here are consistent with other 
preliminary results suggesting that cytoplasmic dCydK is 
responsible for the phosphorylation of (-)-BCH-189 [4]. 
In a recent study using calf thymus dCydK (EC 2.7.1.40). 
Furman et al. 151 reported that (-)-FTC and (+)-FTC have 
similar Km vaiues (23 vs 18 PM), but the V,,, for (-)-FTC 
is aporoximatelv 4-fold greater than for (+)-FTC. The 
difference between these findings and those. reported here 
may reflect different structural requirements for dCydK 
from calf thymus compared to the human T lymphoblast 
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enzyme. These results also emphasize the importance of 
using humanenzyme in order to explain thephosphorylating 
profile observed in human cells. 
The results described here demonstrate that the unnatural 
(-)-enantiomers of FTC and BCH-189 were kineticallv 
superior to the (+)-enantiomers. Similarly, in a study 
using calf thvmus dCvdK, Krenitskv et al. 1191 noted that 
the unnatural t-isomer of araC exhibits a nkarly S-fold 
kinetic advantage over the D-isomer, based on the relative 
V,,,,,/II, values. These data indicate that dCydK can 
accommodate substantial diversity in the sugar moiety of 
nucleoside substrates. 
DDC and the (+)- and (-)-enantiomers of FTC and 
BCH-189 are the first nucleoside analogs for which we 
have observed tower apparent kinetic constants for dCydK 
in the presence of ATP compared to UTP (Table 1). This 
appears to be a function of the 2’,3’-dideoxy structure of 
these compounds. It will be important to examine the 
interaction between these analogs and the nucleoside active 
site for dCydK. 
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